公开(公告)号：US20210145824A1

公开(公告)日：2021-05-20

申请号：US16939627

申请日：2020-07-27

申请人： NOVARTIS PHARMACEUTICALS CORPORATION

发明人： Wang SHEN ,  Kenneth BARR ,  Johan D. OSLOB ,  Min ZHONG

IPC分类号： A61K31/4725 ,  C04B35/632 ,  C07D217/06 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D217/16 ,  C07D401/06 ,  C07D405/14 ,  A61K31/472 ,  A61K45/06 ,  C07D217/26 ,  A61K31/506 ,  A61K31/517

摘要： The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).